Diffusion Pharmaceuticals (DFFN) Stock Pops On COVID-19 News

Diffusion Pharmaceuticals DFFN Stock News

As the overall market stumbles this morning, Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) stock is seeing tremendous gains. In fact, the stock is up more than 100% early on after the company announced that it is working to combat the most deadly aspect of COVID-19. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

DFFN Stock Rockets On Coronavirus Development

In the press release, Diffusion Pharmaceuticals said that it has begun a cooperative research effort with he University of Virginia Health and the Integrated Translational Research Institute of Virginia.

The research collaboration surrounds COVID-19 patients who are experiencing Acute Respiratory Distress Syndrome. Importantly, iTHRIV is a National Institutes of Health-funded Clinical and TranslationalAwards program.

In the release, DFFN pointed to the seriousness of ARDS in COVID-19 patients and the lack of treatment options. The parties involved belive that the oxygen-enhancing mechanism of action of TSC could benefit these patients by mitigating the multiple organ failure that often accompanies systemic hypoxemia. As such, the partnership is working as quickly as possible to develop this potential option for coronavirus patients.

In a statement, David Kalergis, JD/MBA, CEO at DFFN, had the following to offer:

TSC’s oxygen-enhancing mechanism may help address the often-fatal multiple organ failure from ARDS in COVID-19 patients. In addition to UVA/iTHRIV, the Company has begun coordination with researchers from other institutions who have asked to participate in this new program. We have also begun discussions with the FDA. We will issue public updates as warranted by this fast-moving situation.

Why Investors Are So Excited

COVID-19 is a very scary illness. As the pandemic continues to spread around the world, the death toll is rising. In fact, yesterday was the deadliest day in the virus’ history thus far.

As pointed out by Diffusion Pharmaceuticals, Acute Respiratory Distress Syndrome, or ARDS, is one of the most deadly complications associated with the coronavirus. So, a treatment for ARDS would likely provide great benefit to patients, shrinking the death toll and reducing the severity of the condition.

With such strong collaborators, and an option that seems as though it will be effective in the treatment of ARDS in COVID-19 patients, DFFN is definitely a stock for the watch list.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.